Since the completion of the Human Genome Project nearly a decade ago, continuing technological and scientific progress has brought significant advances to the fields of genomics and personalized medicine. As researchers, entrepreneurs, investors and businesses have sought to harness these advances, they have received increasing scrutiny from politicians, regulators, judges and policymakers. This, in turn, has brought a new layer of complexity to an already complicated legal and regulatory landscape.
The Genomics Law Report, a publication of the law firm Robinson, Bradshaw & Hinson, analyzes the legal implications of important developments in the fields of genomics and personalized medicine — including key litigation, legislative, regulatory and policymaking activities — to help make sense of these complex and rapidly changing areas of law and policy.
|John Conley is Kenan Professor of Law at the University of North Carolina and of counsel to Robinson, Bradshaw & Hinson, where he specializes in intellectual property and biotechnology. Full Bio|
GLR Contributing Editor
|Jennifer K. Wagner earned her JD from the University of North Carolina and her PhD in Anthropology from Penn State University. She completed post-doctoral research appointments at Duke University’s Institute for Genome Sciences & Policy and the University of Pennsylvania’s Center for the Integration of Genetic Healthcare Technologies. She recently served in a U.S. Senator’s office as a 2014-2015 AAAS Science & Technology Policy Congressional Fellow. Jennifer is a licensed attorney in Pennsylvania with a small private practice as well as Associate Director of Bioethics Research for Geisinger Health System. She has contributed to Genomics Law Report since 2011 and became a contributing editor in May 2013.|